Gallium (68Ga) gozetotide
Clinical data | |
---|---|
Trade names | Illuccix, Locametz |
Other names | Gallium 68 PSMA-11, Gallium Ga 68 gozetotide (USAN US) |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
License data |
|
Pregnancy category |
|
Intravenous[2] | |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Excretion | Urine[2] |
Identifiers | |
| |
JSmol) | |
| |
|
Gallium (68Ga) gozetotide or Gallium (68Ga) PSMA-11 sold under the brand name Illuccix among others, is a
The most common side effects with gallium (68Ga)-radiolabelled gozetotide are tiredness, nausea (feeling sick), constipation and vomiting.[9]
Gallium (68Ga) gozetotide was approved for medical use in the United States in December 2021,[12][13] and in the European Union in December 2022.[9] It is the first drug approved by the US Food and Drug Administration (FDA) as a PET imaging agent.[11]
Structure
Radiopharmaceuticals based on
Medical uses
Gallium (68Ga) gozetotide is a radioactive diagnostic agent
Ga 68 PSMA-11 injections are used for PET imaging of
History
In the early 2000s, researchers began exploring the use of PSMA as a target for imaging and therapy. The first PSMA-targeted radiotracer was developed using a different radioactive element, technetium-99m. This radiotracer, called 99mTc-MIP-1404, showed promise in preclinical studies but did not perform well in clinical trials.[15]
In 2011, researchers started investigating the use of gallium-68, a different radioactive element, as a more suitable alternative for PSMA-targeted radiotracers. In 2013, the first Ga-PSMA radiotracer was developed by researchers at
Since then, Ga-PSMA has been extensively studied in clinical trials, and it has been found to be a highly effective imaging agent for detecting prostate cancer lesions. It is now widely used in clinical practice, particularly for patients with recurrent prostate cancer and those with high-risk disease.
Initially gallium (68Ga) chloride solution injections used for radiolabelling,[17] in 2019 European Pharmacopoeia mentions gallium (68Ga) DOTATOC injection for radiolabelling and PET imaging.[18]
Ga 68 PSMA-11 is co-developed by University of California, Los Angeles and University of California, San Francisco, they conducted phase III clinical trial.[19] In December 2020, the drug was first approved by US Food and Drug Administration (FDA) for PET imaging.[11]
Mechanism of action
Gallium (68Ga) gozetotide binds with prostate-specific membrane antigen (PSMA).[2] This binds to cells that express PSMA, including malignant prostate cancer cells.[2] The radioactive isotope of gallium, 68Ga is responsible for emitting β+ radiations and X-rays.[2] This helps in recording images by positron emission tomography (PET) and CT scan.[2]
Society and culture
Legal status
On 13 October 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Locametz, intended for the diagnosis of prostate cancer.[20] The applicant for this medicinal product is Novartis Europharm Limited.[20] Locametz was approved for medical use in the European Union in December 2022.[9][21]
Names
Gallium (68Ga) gozetotide is the international nonproprietary name (INN).[22]
References
- ^ a b "AusPAR: Glu-urea-Lys(ahx)-hbed-CC". Therapeutic Goods Administration (TGA). 27 June 2022. Retrieved 17 July 2022.[permanent dead link]
- ^ a b c d e f g h "Gallium GA-68 PSMA-11- gallium ga-68 gozetotide injection, solution". DailyMed. 21 November 2021. Archived from the original on 3 July 2022. Retrieved 27 May 2022.
- ^ "Illuccix Summary Basis of Decision". Health Canada. Archived from the original on 27 May 2023. Retrieved 10 March 2023.
- ^ "Summary Basis of Decision for Locametz". Health Canada. 21 June 2023. Archived from the original on 20 August 2023. Retrieved 20 August 2023.
- ^ "Details for: Locametz". Health Canada. 11 May 2023. Archived from the original on 20 August 2023. Retrieved 20 August 2023.
- ^ "Gallium GA-68 PSMA-11- gallium ga-68 gozetotide injection, solution". DailyMed. 30 November 2021. Archived from the original on 3 July 2022. Retrieved 27 May 2022.
- ^ a b "Illuccix- kit for the preparation of gallium ga 68 gozetotide injection kit". DailyMed. 12 May 2022. Archived from the original on 3 July 2022. Retrieved 27 May 2022.
- ^ a b "Locametz- kit for the preparation of gallium ga 68 gozetotide injection, powder, lyophilized, for solution". DailyMed. 23 March 2022. Archived from the original on 3 July 2022. Retrieved 27 May 2022.
- ^ a b c d e "Locametz EPAR". European Medicines Agency (EMA). 12 October 2022. Archived from the original on 21 December 2022. Retrieved 21 December 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "gallium Ga 68 gozetotide". National Cancer Institute. 2 February 2011. Archived from the original on 18 November 2021. Retrieved 18 November 2021.
- ^ a b c "FDA Approves First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer" (Press release). U.S. Food and Drug Administration (FDA). 2 December 2020. Archived from the original on 4 November 2021. Retrieved 9 November 2021. This article incorporates text from this source, which is in the public domain.
- ^ "Drug Approval Package: Illuccix". U.S. Food and Drug Administration (FDA). 3 August 2022. Archived from the original on 21 December 2022. Retrieved 21 December 2022.
- ^ "Drug Approval Package: Locametz". U.S. Food and Drug Administration (FDA). 2 June 2022. Archived from the original on 21 December 2022. Retrieved 21 December 2022.
- S2CID 202871507.
- PMID 23132604.
- S2CID 26385694.
- ISBN 978-3-7692-6816-4.)
{{cite book}}
: CS1 maint: location missing publisher (link - ISBN 978-3-7692-7453-0.)
{{cite book}}
: CS1 maint: location missing publisher (link - PMID 33443068.
- ^ a b "Locametz: Pending EC decision". European Medicines Agency. 13 October 2022. Archived from the original on 14 October 2022. Retrieved 14 October 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Locametz Product information". Union Register of medicinal products. Archived from the original on 16 December 2022. Retrieved 3 March 2023.
- ^ World Health Organization (2021). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 85" (PDF). WHO Drug Information. 35 (1). Archived (PDF) from the original on 19 April 2021. Retrieved 28 May 2022.
External links
- "Gallium Ga 68 gozetotide". Drug Information Portal. U.S. National Library of Medicine.